Table 5.
Summary of the multivariate analysis of prognostic factors in nasopharyngeal carcinoma (Including ETAR and CXCR4)
| Clinical endpoint | Prognosticator | HR | 95% CI | P value |
|---|---|---|---|---|
|
OS |
CXCR4 Expression |
2.78 |
1.78-4.35 |
<0.001 |
| UICC Stage |
1.51 |
1.15-1.98 |
0.003 |
|
| N classification |
1.47 |
1.16-1.88 |
0.001 |
|
| Gender |
0.48 |
0.29-0.80 |
0.004 |
|
| |
Age |
1.65 |
1.07-2.56 |
0.024 |
|
PFS |
CXCR4 Expression |
2.30 |
1.42-3.72 |
<0.001 |
| ETAR Expression |
2.12 |
1.03-4.36 |
0.04 |
|
| |
N classification |
1.66 |
1.31-2.08 |
<0.001 |
| |
Gender |
0.38 |
0.21-0.72 |
0.003 |
|
DMFS |
CXCR4 expression |
2.52 |
1.42-4.46 |
0.001 |
| ETAR expression |
3.46 |
1.22-9.84 |
0.02 |
|
| |
N classification |
1.96 |
1.48-2.59 |
<0.001 |
| LRRFS | UICC stage | 1.76 | 1.22-2.54 | 0.002 |
CI confidence interval, DMFS distant metastasis-free survival, HR hazard ratio, LRRFS locoregional relapse-free survival, OS overall survival, PFS progression-free survival.